Ad
related to: merckSCBN.org has been visited by 10K+ users in the past month
Search results
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
Reuters via Yahoo Finance· 13 hours ago(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion,...
Merck eyes purchase of ophthalmology company
WFMZ Eastern Pennsylvania and Western New Jersey· 2 hours agoTake Merck, for example. Its blockbuster cancer drug, Keytruda, is now the largest selling drug in the world. In the past few weeks, studies have shown...
Merck to Acquire EyeBio
Morningstar· 13 hours agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today ...
Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patent
Quartz· 9 hours agoPharma giant Merck said on Wednesday that it is acquiring the privately-held eye drug developer...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 6 hours agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Investor's Business Daily· 4 hours agoDow Jones stalwart Merck and Surmodics announced big takeover deals Wednesday, but Merck stock...
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 4 hours agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
Zacks via Yahoo Finance· 8 hours agoMerck KGaA (MKGAF) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Market Watch· 13 hours agoannounced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused...
Merck to Buy Eye Drug Company Eyebiotech for Up to $3 Billion. It’s Doubling Down on Deals.
Barrons.com· 11 hours agoThe pharmaceutical company agrees to buy eye drug company Eyebiotech for up to $3 billion as it...
